Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2003

View Archived Issues

GSK develops new glucocorticoid receptor agonists

New beta3-adrenoceptor agonists identified by Sanofi-Synthelabo team

Gruenenthal patents new NOS inhibitors with utility in migraine therapy

Three related series of adenosine A2A antagonists claimed by Schering-Plough

Sepracor patent covers novel tramadol analogues for pain and other uses

Novel monoamine uptake modulators prepared and tested by Sepracor researchers

Antitumor Cdc25 phosphatase inhibitors designed at Maxia

Short- and long-term efficacy reported for cinacalcet in secondary hyperparathyroidism

Improved iron balance found for deferasirox in iron-loaded patients with beta-thalassemia

Suramin inhibits liver cell apoptosis in vitro and in vivo

Aramchol induces ABCA1-dependent efflux of cholesterol and phospholipids in vitro

Broad crosslicensing agreement between Ipsen and Teijin

Xoma regains rights to Neuprex

Amgen/Wyeth seek approval for fifth indication for anti-TNF therapy

FDA advisory committee schedules Ranexa NDA for review

PI-88 achieves primary efficacy endpoint in multiple myeloma trial

Japanese launch announced for OxyContin

Puricase advances through the clinical pipeline for refractory gout

Angeliq cleared for pan-European launch

AVI BioPharma proceeds towards clinical testing of West Nile virus antisense drug

Major global study examines second-generation HCV combination therapy in nonresponders

First preclinical data supporting AP-23464 as an alternative to Gleevec

Potent inhibitor of in vitro HCV replication presented at EASL meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...